Primary Immune Deficiency (PID) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Primary Immune Deficiency (PID) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Summary

This reports provides a data-driven overview of the current and future competitive landscape in PID therapeutics.

• More than 325,500 diagnosed prevalent cases are anticipated in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast for primary immune deficiency (PID).
• The marketed drugs space for PID is dominated by immunoglobulin-based therapies.
• R&D activity in PID is promising, with five agents in pre-registration stage and 11 in Phase III of development across global markets.
• The PID clinical trials space consists of an almost equal mix of commercial and academic sponsors, with the US emerging as the key country for conducting Phase III trials.
• Partnerships were the most prominent deals type undertaken in the PID space in the past two years.

Scope

GlobalData’s PID: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the PID market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PID market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.